Advance research for this generation and beyond
Our Therapeutic Focus
While the last decade brought breakthroughs for
some bleeding disorders, people with conditions
that lack available prophylactic therapies have
continued waiting for innovation. These patients
have normalized living with unpredictable bleeds,
limiting their activities and independence. At
Hemab, we believe a different future is
possible—one where prevention, not just
management, becomes the standard of care.
HMB-003 for Heavy Menstrual Bleeding (NCT07798505)
HMB-003 is being evaluated in a Phase 1 clinical trial for heavy menstrual bleeding. HMB-003 is a peptide-based plasmin inhibitor with an extended half-life. Its durable pharmacokinetic profile supports once-per-cycle subcutaneous dosing, offering a convenient alternative to frequent-dosing antifibrinolytic regimens.
VELORA Pioneer — HMB-002 for VWD
Velora Pioneer is a Phase 1/2 clinical trial of HMB-002 for Von Willebrand Disease (VWD). HMB-002 is being developed as a prophylactic treatment to support restoration of hemostasis in people with VWD using a convenient subcutaneous treatment administration.
VELORA Discover — Screening Study for VWD
Velora Discover is a prospective natural history study of patients with Von Willebrand Disease (VWD) to establish baseline disease characteristics, bleeding patterns, and quality of life measures. The purpose of the study is to provide contemporary control data and contextualize treatment effects observed in the interventional components of the Velora Pioneer clinical trial.
Sutacimig for FVIID
This Phase 2 clinical trial evaluates pharmacokinetics, pharmacodynamics, and preliminary safety and tolerability of single ascending doses of sutacimig in patients with Factor VII deficiency. This trial aims to establish proof-of-concept by demonstrating sutacimig’s ability to increase Factor VII levels in patients with Factor VII deficiency.
Sutacimig for GT
The goal of this Phase 1/2 clinical trial is to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical efficacy of sutacimig in patients with Glanzmann thrombasthenia. We have completed the Part A (single ascending dose) and Part B (three-month multiple ascending dose) portions of the trial, and the Part C (long-term extension up to 24 months) portion is currently ongoing.